Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]

  • Awaiting development
  • GID-TA11766
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Lutetium within its marketing authorisation for treating prostate cancer